Clinical-Stage Biopharmaceutical Company HOTH Says It Is on a Mission to Develop Next-Generation Therapeutics to Meet Patient Needs

Photo by Roberto Sorin on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

The medical research field is one of the most advancing industries in the world. As diseases keep evolving, medical scientists continue to discover modern ways to deal with them at their earliest stages. One of the companies that says it is leveraging the potential of therapeutics to treat diseases and infections is Hoth Therapeutics HOTH.

Hoth Therapeutics is a clinical-stage biopharmaceutical company that uses cutting-edge scientific research to find and develop early-stage therapeutics that will transform how diseases are managed and treated. Hoth states that it seeks out drugs that are often overlooked but have the potential to improve treatments and deal with adverse effects patients experienced from some medical therapies. Some of the projects underway at Hoth include BioLexa, and HT-001.

• BioLexa

BioLexa is a patented, antimicrobial topical formulation under development for the treatment of diseases caused by Staphylococcal biofilms. Bacterial biofilms are unique communities of bacteria that stick to a surface and to other bacteria — most of the time with a protective extracellular matrix.

Mature bacterial biofilms often produce chronic and recurrent infections that are hard to treat because the biofilm creates a barrier effect to antibiotics. BioLexa prevents Staphylococcal biofilm formation, which leaves the bacteria susceptible to antimicrobial treatment.

BioLexa is under development for the treatment of eczema, surgical site infection, diabetic wound care and aesthetic dermatology.

Recently, the company announced positive cohort 1 results of its 1st human clinical trial for the treatment of dermatitis, also known as eczema, using BioLexa.

• HT-001

HT-001 is a formulation under development for patients with mild to moderate rash and skin disorders associated with repeated courses of tyrosine kinase inhibitor or epidermal growth factor receptor (EGFR) inhibitor therapy, which is used in the treatment of cancers with EGFR up-regulation, such as non-small cell lung cancer.

HT-001 is targeted to treat EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy. 

What Sets Hoth Therapeutics Apart

While most companies in the biopharmaceutical products industry are more focused on meeting the demand for products, Hoth says it is addressing unmet patient needs. That's why most of its research is focused on dealing with unfavorable, adverse effects associated with medical therapies.

The Global Market for Biopharmaceuticals

In 2020, the global biopharmaceutical industry market was valued at more than $320 billion, and analysts predict in 2026 it will be worth $400 billion with a compound annual growth rate (CAGR) of 7.32% over the forecasted period of 2021-2026.

The EGFR Inhibitor Skin Toxicity market alone is predicted to grow from $52 million in 2018 to $391 million by the end of 2030. According to research, the atopic dermatitis market is predicted to grow from $6.4 billion in 2017 to $18.3 billion by the end of 2027.

An increase in the elderly population, the increase in chronic diseases and the growing acceptance of biopharmaceuticals in the treatment of previously untreated diseases are some of the major drives fueling the growth of the market.

Some of the key players in the biopharmaceutical space include Johnson & Johnson JNJ, Intercept Pharmaceuticals, Inc. (ICPT), Pfizer Inc. PFE and AbbVie ABBV.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.